{"id":755031,"date":"2023-05-04T12:27:05","date_gmt":"2023-05-04T16:27:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/"},"modified":"2023-05-04T12:27:05","modified_gmt":"2023-05-04T16:27:05","slug":"capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/","title":{"rendered":"Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11"},"content":{"rendered":"

\nCompany to Host Conference Call, May 11, 2023, at 4:30 p.m. ET
\n<\/h2>\n
\n

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics<\/a> (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 11, 2023. Management will then host a webcast and conference call at 4:30 p.m. ET on May 11.<\/p>\n\n\n\n\n\n\n
\n

Title:<\/strong><\/p>\n<\/td>\n

\n

Capricor Therapeutics First Quarter 2023 Financial Results and Recent Corporate Update Conference Call and Webcast<\/td>\n<\/tr>\n

\n Date:<\/strong>\n <\/td>\nThursday, May 11, 2023<\/td>\n<\/tr>\n
\n Time:<\/strong>\n <\/td>\n4:30 p.m. ET<\/td>\n<\/tr>\n
\n Conference Call Details:<\/strong>\n <\/td>\nToll-Free: 1-855-327-6837
International: 1-631-891-4304
Conference ID: 10021769<\/p>\n

Participants can use Guest dial-in #s above and be answered by an operator or click the Call me\u2122 link<\/a> for instant telephone access to the event.<\/p>\n<\/td>\n<\/tr>\n

\n Webcast:<\/strong>\n <\/td>\n\n Webcast Link – Click Here<\/a>
\n \n <\/td>\n<\/tr>\n<\/table>\n

A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company\u2019s website<\/a>.<\/p>\n

\n About Capricor Therapeutics<\/strong>\n <\/p>\n

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor\u2019s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor\u2019s focus is on developing exosomes capable of delivering nucleic acids, including mRNA, as well as proteins to treat or prevent a variety of diseases. For more information, visit\u00a0capricor.com<\/a>, and follow Capricor on\u00a0Facebook<\/a>,\u00a0Instagram<\/a> and\u00a0Twitter<\/a>.<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>\n <\/p>\n

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor\u2019s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams and revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor\u2019s management team\u2019s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words \u201cbelieves,\u201d \u201cplans,\u201d \u201ccould,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cestimates,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor\u2019s business is set forth in Capricor\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on March 17, 2023. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.<\/p>\n

\n CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor\u2019s exosome-based candidates have been approved for clinical investigation.<\/em>\n <\/p>\n

\n For more information, please contact:<\/strong>\n <\/p>\n

\n Capricor Media Contact:<\/strong>
\n
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com<\/a>
212.896.1204<\/p>\n

\n Capricor Investor Contact:<\/strong>
\n
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com<\/a>
617.435.6602<\/p>\n

\n Capricor Company Contact:<\/strong>
\n
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com<\/a>
858.727.1755<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company to Host Conference Call, May 11, 2023, at 4:30 p.m. ET SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 11, 2023. Management will then host a webcast and conference call at 4:30 p.m. ET on May 11. Title: Capricor Therapeutics First Quarter 2023 Financial Results and Recent Corporate Update Conference Call and Webcast Date: Thursday, May 11, 2023 Time: 4:30 p.m. ET Conference Call Details: Toll-Free: 1-855-327-6837International: 1-631-891-4304Conference ID: 10021769 Participants … <\/p>\n

Continue reading “Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-755031","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCapricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to Host Conference Call, May 11, 2023, at 4:30 p.m. ET SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 11, 2023. Management will then host a webcast and conference call at 4:30 p.m. ET on May 11. Title: Capricor Therapeutics First Quarter 2023 Financial Results and Recent Corporate Update Conference Call and Webcast Date: Thursday, May 11, 2023 Time: 4:30 p.m. ET Conference Call Details: Toll-Free: 1-855-327-6837International: 1-631-891-4304Conference ID: 10021769 Participants … Continue reading "Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T16:27:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTM5NiM1NTczNjcyIzUwMDA2ODU2Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11\",\"datePublished\":\"2023-05-04T16:27:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\\\/\"},\"wordCount\":642,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTM5NiM1NTczNjcyIzUwMDA2ODU2Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\\\/\",\"name\":\"Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTM5NiM1NTczNjcyIzUwMDA2ODU2Ng==\",\"datePublished\":\"2023-05-04T16:27:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTM5NiM1NTczNjcyIzUwMDA2ODU2Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTM5NiM1NTczNjcyIzUwMDA2ODU2Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/","og_locale":"en_US","og_type":"article","og_title":"Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11 - Market Newsdesk","og_description":"Company to Host Conference Call, May 11, 2023, at 4:30 p.m. ET SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 11, 2023. Management will then host a webcast and conference call at 4:30 p.m. ET on May 11. Title: Capricor Therapeutics First Quarter 2023 Financial Results and Recent Corporate Update Conference Call and Webcast Date: Thursday, May 11, 2023 Time: 4:30 p.m. ET Conference Call Details: Toll-Free: 1-855-327-6837International: 1-631-891-4304Conference ID: 10021769 Participants … Continue reading \"Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T16:27:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTM5NiM1NTczNjcyIzUwMDA2ODU2Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11","datePublished":"2023-05-04T16:27:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/"},"wordCount":642,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTM5NiM1NTczNjcyIzUwMDA2ODU2Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/","name":"Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTM5NiM1NTczNjcyIzUwMDA2ODU2Ng==","datePublished":"2023-05-04T16:27:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTM5NiM1NTczNjcyIzUwMDA2ODU2Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTM5NiM1NTczNjcyIzUwMDA2ODU2Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-present-first-quarter-2023-financial-results-and-recent-corporate-update-on-may-11\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=755031"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755031\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=755031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=755031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=755031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}